The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
Yesterday marked day one of the 2026 ASCO Genitourinary (GU) Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies that are ...
Hosted on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
For men diagnosed with high-risk prostate cancer, surgery is often part of the treatment plan, but nearly half of all patients who undergo radical prostatectomy for high-risk disease will see their ...
Dr Oliver Sartor of the Transformational Prostate Cancer Research Center in New Orleans reviews key prostate cancer studies from the 2026 American Society of Clinical Oncology Annual Meeting. He ...
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label for metastatic castration-resistant prostate cancer (mCRPC ...
CHICAGO -- A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen deprivation therapy (ADT) significantly reduced the risk of metastasis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results